Coherus Oncology, Inc.
CHRS Healthcare Biotechnology
In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.
Follow CHRS
Coherus Oncology, Inc. (CHRS) Altman Z-score
Coherus Oncology, Inc.'s Altman Z-score for fiscal 2025 is −8.83, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −8.83 | (2.90) |
| FY2024 | −5.93 | (2.27) |
| FY2023 | −3.67 | 0.36 |
| FY2022 | −4.03 | (3.08) |
| FY2021 | −0.95 | (3.07) |
| FY2020 | 2.12 | 0.30 |
| FY2019 | 1.82 | 10.21 |
| FY2017 | −8.39 | (8.25) |
| FY2016 | −0.14 | 2.98 |
| FY2015 | −3.12 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.26 | — | 0.31 | |
| Retained earnings / total assets | (5.35) | — | −7.49 | |
| EBIT / total assets | (0.70) | — | −2.31 | |
| Market value of equity / total liabilities | 0.84 | — | 0.51 | |
| Sales / total assets | 0.16 | — | 0.16 | |
| Altman Z-score | Distress zone | −8.83 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −20.15 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | 4.0× |
| ORMP Oramed Pharmaceuticals Inc. compare | 1.9× |
| WHWK Whitehawk Therapeutics, Inc. compare | 1.5× |
| MDWD MediWound Ltd. compare | −1.1× |
| DTIL Precision BioSciences, Inc. compare | −4.3× |
| ADAG Adagene Inc. Sponsored ADR compare | −4.6× |
| CHRS Coherus Oncology, Inc. | −8.8× |
| IPHA Innate Pharma S.A. Sponsored ADR compare | −11.2× |
| VRXA Veraxa Biotech AG compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets